Who we are

About Alacris Theranostics

Alacris Theranostics GmbH is a Berlin-based company founded in 2008 by pioneers in the fields of technology development, genomics, new generation sequencing applications and systems biology.The company’s core technologies have been in continuous development since 2000, with the aim of translating research innovations into direct benefits for patients and society, enabling novel approaches in precision medicine.

Our mission is to develop innovative concepts and sustainable solutions for revolutionizing healthcare, biomarker discovery and drug development, with an initial focus on molecular oncology and precision medicine.

Our technologies are already being used within clinics, and have fostered a number of research projects in partnership with academia as well as biotechnology and pharmaceutical companies.

Our team and their commitment

The Alacris team has long-standing expertise in interdisciplinary approaches, combining sequencing technologies, large-scale operations, advanced computing, high dimensional data analytics and bioinformatics systems, allowing us to offer a wide range of leading-edge services. We are working closely together with clinicians to adapt our products to medical needs, bridging technical advances with medical competence.Our experienced staff is dedicated to applying their know-how to provide outstanding, quality-certified, personalized services to our customers. We are committed to delivering excellence.

We know that time matters: we work hard to deliver your data in the shortest possible time frame without compromising on quality.

Your data are safe: we adhere to strict procedures and regulations regarding data safety, data confidentiality, and data protection.

Privacy is very important to us: all requests remain strictly confidential.

Leadership team

Hans Lehrach: Founder, Chairman of the scientific advisory board

Hans Lehrach pioneered the development of cloning techniques, positional cloning and genome scale analysis techniques at Harvard Medical School (USA) and at the EMBL (Germany).He was involved from the beginning in the initial plans to sequence the human genome. At the ICRF (London), he developed innovative technologies and the first array-based robotics for genome wide gene function analyses and large-scale genome mapping, the core method behind the first human genome sequence. Since 1994 he has been director at the Max Planck Institute for Molecular Genetics (MPIMG, Berlin), carrying out pioneering work in functional genomics, genome sequencing, and cancer systems medicine. He is founder of multiple companies, including Sequana Therapeutics (San Diego), GPC Biotech (Munich-Martinsried) and Atlas Biolabs (Berlin).

George Church: Founder, member of the scientific advisory board

George Church is Professor of Genetics at Harvard Medical School and at MIT, Director of PersonalGenomes.org). He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science.  He is co-author of 425 publications, 95 patents, developed methods used for the first genome sequence (1994) and million-fold cost reductions since via NGS and nanopores. His innovations have contributed to most, if not all, “next generation” DNA sequencing methods and companies (CGI-BGI, Life Tech, Illumina, Nanopore), and to a wide range of other areas, including new genome editing and iPS cell redifferentiation strategies. He co-initiated the BRAIN Initiative (2011) and Genome Projects (1984, 2005) to provide and interpret the world’s only open-access personal precision medicine datasets). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies.  He is founder of several companies in the fields of medical diagnostics (Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics (Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive)

Marie-Laure Yaspo: Founder, Chief Scientific Officer

Dr. Marie-Laure Yaspo did her postdoctoral research at the Imperial Cancer research Fund (London, UK). Since 1996 she has been a research group leader at the Max Planck Institute for Molecular Genetics (MPIMG, Berlin). She is currently head of the Otto Warburg Laboratory “Gene Regulation and Systems Biology of Cancer’ at the MPIMG. M-L Yaspo coordinated the International Consortium for mapping and sequencing Human chromosome 21 within the Human Genome Project. She participates in the International Cancer Genome consortium (ICGC early-onset prostate cancer and IGCG pediatric brain tumors) and the European Blueprint project. She coordinated the data analysis within the Innovative Medicines Initiative Oncotrack project. Her team has sequenced and analyzed more than 1,000 tumor and tissue transcriptomes. Dr. Yaspo coordinates Treat20Plus, a translational study carried out together with the Charité Comprehensive Cancer Center in Berlin, aimed at optimizing treatment of patients with metastatic melanoma.

Bodo Lange: Chief Executive Officer

Dr. Bodo Lange carried out postdoctoral research at the University of Manchester, KARC in Kobe Japan and EMBL Heidelberg. He was group leader at the Max Planck Institute for Molecular Genetics (MPIMG, Berlin) and a lecturer at the Freie Universität, Berlin. He led the BMBF-funded National Genome Research Network Consortium MUTANOM, investigating the effects of cancer driver variants on protein-interaction and signaling networks. He became Chief Executive Officer of Alacris in September 2011. Under his stewardship, Alacris has built a sequencing laboratory for clinical samples as well as developed an IT infrastructure for bioinformatics and modeling. He has published over 30 research articles in the area of signal transduction and cancer biology. Dr. Lange was part of the executive committee of the IMI funded OncoTrack project and is coordinator of the Horizon 2020 project CanPathPro, two pre-clinical projects in the field of predictive modeling of cancer signaling pathways.